The interaction between GLP-1 medications and oral hormonal treatments can affect absorption and efficacy
For premenopausal women , discussion should cover: Contraceptive reliability and the need for additional precautions or alternative methods The possibility of improved fertility with weight loss, particularly in women with PCOS or obesity-related subfertility Monitoring for menstrual cycle changes, which may indicate improving metabolic health Pregnancy planning, as Mounjaro should be discontinued at least one month before conception according to the UK product information, and should be avoided during pregnancy and breastfeeding Risk of hypoglycaemia if also taking insulin or sulfonylureas, which may require dose adjustments of these medications For perimenopausal and postmenopausal women , considerations include: Potential reduction in peripheral oestrogen production with significant weight loss Monitoring for changes in menopausal symptoms Continued appropriateness of hormone replacement therapy (HRT) if already prescribed, noting that Mounjaro does not contraindicate HRT use Consider non-oral HRT routes if significant gastrointestinal symptoms occur Women with hormone-sensitive conditions such as oestrogen-receptor-positive breast cancer history, endometriosis, or uterine fibroids should discuss Mounjaro use with their oncologist or specialist
Semaglutide has transformed weight management for millions of people, with clinical trials showing an average weight loss of 15% over 68 weeks in adults with obesity
Notice: This product is provided strictly for laboratory research use only
Mapping the effectiveness and risks of GLP-1 receptor agonists
Youre having a miscarriage Miscarriages usually occur within the first 12 weeks of pregnancy, which is why most people prefer to announce theyre expecting after they reach this milestone
